Cognition Therapeutics (CGTX) announced that its expanded access program has reached full enrollment. Each of the individuals enrolled in the program are being treated with 100 mg of oral zervimesine daily for up to one year. The program was made possible through a generous donation from the family of a participant in the Phase 2 SHIMMER study of zervimesine in dementia with Lewy bodies, DLB. “We are grateful to the family who made it possible to provide expanded access to zervimesine for people who were in the Phase 2 DLB study,” stated Lisa Ricciardi, president and CEO of Cognition Therapeutics. “The efforts of our dedicated investigators and our clinical operations team made it possible to complete enrollment in only three months.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGTX:
- Cognition Therapeutics presents Phase 3 plan for zervimesine in Alzheimer’s
- Cognition Therapeutics price target raisd to $3 from $2 at B. Riley
- Cognition Therapeutics completes enrollment in Phase 2 study of Zervimesine
- Optimistic Buy Rating for Cognition Therapeutics Amid Promising Developments in Alzheimer’s and Dementia Treatment
- Cognition Therapeutics Advances Alzheimer’s Drug Development